Metformin remains a leading candidate for pharmacologic longevity intervention

Metformin remains a leading candidate for pharmacologic longevity intervention

Metformin continues to occupy a unique position in longevity medicine because of its long track record and well understood safety profile. Originally introduced as a first line therapy for type 2 diabetes, it has since been studied for its broader effects on aging related pathways. Much of the early enthusiasm came from observational data suggesting lower mortality in patients taking metformin compared to other therapies. That observation led researchers to consider whether the drug might influence aging itself rather than just glycemic control. A widely cited Cell review on metformin and aging helped frame this possibility by outlining its effects on insulin signaling and cellular metabolism. Subsequent work, including a review of metformin as anti aging therapy, has supported the idea while also highlighting important limitations. The field is now waiting on more definitive clinical evidence. The ongoing Metformin in Longevity Study is designed to directly test whether the drug can delay multiple age related diseases. At the same time, not all data has been uniformly supportive. A critical review of lifespan evidence has questioned whether the benefits are as broad as initially thought. Clinicians are increasingly being asked whether metformin should be used preventively in otherwise healthy individuals. That question is harder to answer than it first appears. While the drug is generally safe, its effects outside of diabetes remain less certain. The distinction between improving metabolic markers and extending lifespan is important. For now, metformin remains promising but unproven as a true longevity therapy.